CT-P13, a biosimilar of infliximab, has just entered the European market, but clinical data are scarce so far. In a recent study, 83 patients with IBD were switched from infliximab to CT-P13 to investigate the safety, efficacy, pharmacokinetic profile and immunogenicity of CT-P13. Median change in disease activity was zero and median levels of C-reactive protein and faecal calprotectin did not change during follow-up. In addition, no serious adverse events were observed. Thus, switching to CT-P13 does not have a negative effect on short-term clinical outcomes.
References
Smits, L. J. et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J. Crohns Colitis http://dx.doi.org/10.1093/ecco-jcc/jjw087 (2016)
Rights and permissions
About this article
Cite this article
Leake, I. Safety and efficacy of switching to biosimilars in IBD. Nat Rev Gastroenterol Hepatol 13, 314 (2016). https://doi.org/10.1038/nrgastro.2016.79
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2016.79
